Development of autogenous vaccine for effective control of Infectious coryza in chicken

Abstract

Preliminary results of the population-based surveillance showed a high incidence rate of CAP, particularly in elderly subjects. Based on this data a pilot vaccination program with PCV13 was implemented by the National and Provincial Ministry of Health offering PCV13 to subjects 65 years and older in Roca City. During a two years period 39% of subjects 65 years and older received PCV13.The aim of this analysis is to assess effectiveness of vaccination program to prevent all cause CAP in subjects 65 years and older.Methods & Materials: Cohort study assessed vaccine effectiveness in preventing CAP among adults 3 65 years and older. Data were gathered from the population-based surveillance database paired with national immunization registry during 2014-2016. Vaccine effectiveness was calculated (1 -(Incidence [vaccinated] ÷ Incidence [unvaccinated]). Multivariable logistic regression was performed, adjusted odds ratios (OR) were computed to obtain vaccine effectiveness (1-OR). We adjusted vaccine effectiveness for influenza vaccination status, age, chronic obstructive pulmonary (COPD), cardiovascular disease, diabetes and nephropathic diseases.Results: During the study period 3640 adults 65 years and older were vaccinated and 34 (0.93%) suffered CAP. In 5672 unvaccinated adults 65 years and older, 467 (8.23%) suffered the same event.Vaccine effectiveness was 90.0% (CI 95%: 85.0%-93.0%), p < 0.01.Adjusted vaccine effectiveness for influenza vaccination status, age, COPD, cardiovascular disease, diabetes and nephropathic diseases was 62.0% (CI 95%: 40.0-75.0), p < 0.01. Conclusion:Our results show a 62% effectiveness to prevent all cause CAP in adults 65 years and older. Studies of effectiveness are relevant to determine the role of PCV13 to prevent CAP in adults.